Non-Hodgkin Lymphoma - Pipeline Review, H2 2014

Non-Hodgkin Lymphoma - Pipeline Review, H2 2014

Oct 2014 Global Markets Direct Lymphoma445 Pages Price :
$ 2000
Non-Hodgkin Lymphoma - Pipeline Review, H2 2014

Summary

Global Markets Directs, Non-Hodgkin Lymphoma - Pipeline Review, H2 2014, provides an overview of the Non-Hodgkin Lymphomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Non-Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
uticals, Inc. 38
Actinium Pharmaceuticals, Inc. 39
AlphaMab Co., Ltd 40
Amgen Inc. 41
Astellas Pharma Inc. 42
Astex Pharmaceuticals, Inc. 43
Avipep Pty Ltd 44
Bayer AG 45
BioInvent International AB 46
Biothera, Inc. 47
Bristol-Myers Squibb Company 48
Calithera Biosciences, Inc. 49
Celgene Corporation 50
Celltrion, Inc. 51
CIMAB S.A. 52
Conkwest, Inc. 53
Constellation Pharmaceuticals, Inc. 54
Cornerstone Pharmaceuticals, Inc. 55
CTI BioPharma Corp. 56
Curis, Inc. 57
Dicerna Pharmaceuticals, Inc. 58
Dynavax Technologies Corporation 59
Eisai Co., Ltd. 60
Eli Lilly and Company 61
Epirus Biopharmaceuticals, Inc. 62
EpiZyme, Inc. 63
F. Hoffmann-La Roche Ltd. 64
Fountain Biopharma Inc. 65
Gamida Cell Ltd. 66
Genentech, Inc. 67
Gilead Sciences, Inc. 68
GlaxoSmithKline plc 69
Grupo Ferrer Internacional, S.A. 70
Hetero Drugs Limited 71
Immunomedics, Inc. 72
Inbiopro Solutions Pvt. Ltd. 73
Innovent Biologics, Inc. 74
Johnson & Johnson 75
Kainos Medicine, Inc. 76
Karyopharm Therapeutics, Inc. 77
Merck & Co., Inc. 78
Millennium Pharmaceuticals, Inc. 79
Mirna Therapeutics, Inc. 80
Mission Therapeutics Ltd 81
MorphoSys AG 82
Novartis AG 83
NovImmune SA 84
NuCana BioMed Limited 85
Oncobiologics, Inc. 86
Otsuka Holdings Co., Ltd. 87
Oxford BioTherapeutics Ltd 88
Panacea Biotec Limited 89
Pfizer Inc. 90
Pharmacyclics, Inc. 91
Polaris Group 92
Portola Pharmaceuticals, Inc. 93
ProNAi Therapeutics, Inc. 94
Richter Gedeon Nyrt. 95
Sanofi 96
Seattle Genetics, Inc. 97
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 98
Shanghai Henlius Biotech Co., Ltd. 99
Sigma-Tau S.p.A. 100
Spectrum Pharmaceuticals, Inc. 101
Supratek Pharma Inc. 102
Taiwan Liposome Company, Ltd. 103
Tekmira Pharmaceuticals Corp. 104
TG Therapeutics, Inc. 105
The International Biotechnology Center (IBC) Generium 106
Tolero Pharmaceuticals, Inc. 107
Transgene Biotek Limited 108
Vivia Biotech, S.L. 109
Xenetic Biosciences plc 110
Zymeworks Inc. 111
Non-Hodgkin Lymphoma - Therapeutics Assessment 112
Assessment by Monotherapy Products 112
Assessment by Combination Products 113
Assessment by Target 114
Assessment by Mechanism of Action 120
Assessment by Route of Administration 126
Assessment by Molecule Type 128
Drug Profiles 130
(19)-3s - Drug Profile 130
abexinostat hydrochloride - Drug Profile 131
AG-221 - Drug Profile 133
AGS-67E - Drug Profile 135
alisertib - Drug Profile 136
alvocidib hydrochloride - Drug Profile 140
AMG-319 - Drug Profile 141
Antibody Conjugate for Non-Hodgkin lymphoma - Drug Profile 142
AT-7519 - Drug Profile 143
AVP-5 - Drug Profile 146
bendamustine hydrochloride - Drug Profile 147
bendamustine hydrochloride - Drug Profile 149
BI-1206 - Drug Profile 150
blinatumomab - Drug Profile 151
BMS-986016 - Drug Profile 154
brentuximab vedotin - Drug Profile 155
CB-839 - Drug Profile 160
CC-115 - Drug Profile 161
CC-122 - Drug Profile 162
CC-223 - Drug Profile 164
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 165
Cell Therapy 3 for Oncology - Drug Profile 166
Cell Therapy for Hematological Malignancies - Drug Profile 167
Cell Therapy for Oncology - Drug Profile 168
Cell Therapy for Oncology - Drug Profile 169
Cell Therapy for Oncology and Infectious Diseases - Drug Profile 170
Cell Therapy to Inhibit CD19 for Non-Hodgkin Lymphoma - Drug Profile 171
Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 172
Cell Therapy to Target CD30 for Relapsed and Refractory Lymphomas - Drug Profile 173
cerdulatinib - Drug Profile 174
copanlisib - Drug Profile 175
CPI-0610 - Drug Profile 178
CPI-613 - Drug Profile 179
CST-103 - Drug Profile 181
CUDC-907 - Drug Profile 182
daratumumab - Drug Profile 184
dasatinib - Drug Profile 187
dasiprotimut-T - Drug Profile 190
DCRM-1711 - Drug Profile 192
Dendritic Cell Therapy for Oncology - Drug Profile 193
Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile 194
DMS-612 - Drug Profile 195
E-7438 - Drug Profile 196
EPZ-5687 - Drug Profile 198
FB-811 - Drug Profile 200
FIB-114 - Drug Profile 201
GNR-022 - Drug Profile 202
GS-9973 - Drug Profile 203
GSK-2816126 - Drug Profile 204
I-Tenatumomab - Drug Profile 205
IBPM-001RX - Drug Profile 206
IGN-002 - Drug Profile 207
IMMU-110 - Drug Profile 208
IMMU-114 - Drug Profile 210
Imprime PGG - Drug Profile 211
Iomab-B - Drug Profile 215
JCAR-014 - Drug Profile 217
KM-301 - Drug Profile 218
KML-001 - Drug Profile 219
KN-001 - Drug Profile 221
lenalidomide - Drug Profile 222
LMP-400 - Drug Profile 225
LMP-776 - Drug Profile 227
LY-2780301 - Drug Profile 228
MK-2206 - Drug Profile 229
MN-2 - Drug Profile 232
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 233
Monoclonal Antibody 2 Conjugates for Cancer - Drug Profile 234
Monoclonal Antibody to Inhibit CD20 for Non-Hodgkin Lymphoma and Rheumatoid Arthritis - Drug Profile 235
MOR-208 - Drug Profile 236
MRX-34 - Drug Profile 238
NI-1701 - Drug Profile 240
NiCord - Drug Profile 241
NSC-678515 - Drug Profile 242
NUC-1031 - Drug Profile 243
obinutuzumab - Drug Profile 245
Oncohist - Drug Profile 247
OPB-51602 - Drug Profile 249
pegargiminase - Drug Profile 251
pembrolizumab - Drug Profile 254
PF-05082566 - Drug Profile 257
pictilisib - Drug Profile 258
pixantrone dimaleate - Drug Profile 260
PNT-2258 - Drug Profile 264
procarbazine hydrochloride - Drug Profile 266
PUH-71 - Drug Profile 267
ricolinostat - Drug Profile 269
rituximab biosimilar - Drug Profile 271
rituximab biosimilar - Drug Profile 273
rituximab biosimilar - Drug Profile 274
rituximab biosimilar - Drug Profile 275
rituximab biosimilar - Drug Profile 276
rituximab biosimilar - Drug Profile 277
rituximab biosimilar - Drug Profile 278
rituximab biosimilar - Drug Profile 279
rituximab biosimilar - Drug Profile 280
rituximab biosimilar - Drug Profile 281
rituximab biosimilar - Drug Profile 282
RP-5264 - Drug Profile 283
SAR-650984 - Drug Profile 284
SD-101 - Drug Profile 285
selinexor - Drug Profile 287
SGN-CD70A - Drug Profile 290
SH-7139 - Drug Profile 291
Small Molecule for Hematologic Malignancies - Drug Profile 293
Small Molecules to Inhibit GLUT4 for Oncology - Drug Profile 294
StemEx - Drug Profile 295
TBL-0306L - Drug Profile 296
TG-1101 + TGR-1202 - Drug Profile 297
tisagenlecleucel-T - Drug Profile 298
TKM-PLK1 - Drug Profile 300
veltuzumab - Drug Profile 302
venetoclax - Drug Profile 305
vincristine sulfate - Drug Profile 308
vincristine sulfate liposomal - Drug Profile 311
vinorelbine tartrate - Drug Profile 312
vinorelbine tartrate liposomal - Drug Profile 313
Vivia-009 - Drug Profile 315
X-396 - Drug Profile 316
ZW-34 - Drug Profile 317
Non-Hodgkin Lymphoma - Recent Pipeline Updates 318
Non-Hodgkin Lymphoma - Dormant Projects 423
Non-Hodgkin Lymphoma - Discontinued Products 426
Non-Hodgkin Lymphoma - Product Development Milestones 427
Featured News & Press Releases 427
Appendix 436
Methodology 436
Coverage 436
Secondary Research 436
Primary Research 436
Expert Panel Validation 436
Contact Us 437
Disclaimer 437

List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2014 21
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2014 22
Number of Products under Development by Companies, H2 2014 24
Number of Products under Development by Companies, H2 2014 (Contd..1) 25
Number of Products under Development by Companies, H2 2014 (Contd..2) 26
Number of Products under Development by Companies, H2 2014 (Contd..3) 27
Number of Products under Development by Companies, H2 2014 (Contd..4) 28
Number of Products under Development by Companies, H2 2014 (Contd..5) 29
Number of Products under Investigation by Universities/Institutes, H2 2014 30
Comparative Analysis by Late Stage Development, H2 2014 32
Comparative Analysis by Clinical Stage Development, H2 2014 33
Comparative Analysis by Early Stage Development, H2 2014 34
Comparative Analysis by Unknown Stage Development, H2 2014 35
Products under Development by Companies, H2 2014 36
Products under Development by Companies, H2 2014 (Contd..1) 37
Products under Development by Companies, H2 2014 (Contd..2) 38
Products under Development by Companies, H2 2014 (Contd..3) 39
Products under Development by Companies, H2 2014 (Contd..4) 40
Products under Development by Companies, H2 2014 (Contd..5) 41
Products under Development by Companies, H2 2014 (Contd..6) 42
Products under Investigation by Universities/Institutes, H2 2014 43
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H2 2014 44
Non-Hodgkin Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H2 2014 45
Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2014 46
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 47
Non-Hodgkin Lymphoma - Pipeline by AlphaMab Co., Ltd, H2 2014 48
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H2 2014 49
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H2 2014 50
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 51
Non-Hodgkin Lymphoma - Pipeline by Avipep Pty Ltd, H2 2014 52
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2014 53
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H2 2014 54
Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc., H2 2014 55
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 56
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H2 2014 57
Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2014 58
Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H2 2014 59
Non-Hodgkin Lymphoma - Pipeline by CIMAB S.A., H2 2014 60
Non-Hodgkin Lymphoma - Pipeline by Conkwest, Inc., H2 2014 61
Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014 62
Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 63
Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp., H2 2014 64
Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H2 2014 65
Non-Hodgkin Lymphoma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2014 66
Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2014 67
Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H2 2014 68
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H2 2014 69
Non-Hodgkin Lymphoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 70
Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H2 2014 71
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 72
Non-Hodgkin Lymphoma - Pipeline by Fountain Biopharma Inc., H2 2014 73
Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H2 2014 74
Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H2 2014 75
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2014 76
Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline plc, H2 2014 77
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 78
Non-Hodgkin Lymphoma - Pipeline by Hetero Drugs Limited, H2 2014 79
Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H2 2014 80
Non-Hodgkin Lymphoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 81
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H2 2014 82
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2014 83
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H2 2014 84
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 85
Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2014 86
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 87
Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H2 2014 88
Non-Hodgkin Lymphoma - Pipeline by Mission Therapeutics Ltd, H2 2014 89
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2014 90
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2014 91
Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H2 2014 92
Non-Hodgkin Lymphoma - Pipeline by NuCana BioMed Limited, H2 2014 93
Non-Hodgkin Lymphoma - Pipeline by Oncobiologics, Inc., H2 2014 94
Non-Hodgkin Lymphoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 95
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H2 2014 96
Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H2 2014 97
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H2 2014 98
Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2014 99
Non-Hodgkin Lymphoma - Pipeline by Polaris Group, H2 2014 100
Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 101
Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2014 102
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H2 2014 103
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2014 104
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2014 105
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2014 106
Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2014 107
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2014 108
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 109
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H2 2014 110
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2014 111
Non-Hodgkin Lymphoma - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 112
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2014 113
Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2014 114
Non-Hodgkin Lymphoma - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 115
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H2 2014 116
Non-Hodgkin Lymphoma - Pipeline by Vivia Biotech, S.L., H2 2014 117
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences plc, H2 2014 118
Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc., H2 2014 119
Assessment by Monotherapy Products, H2 2014 120
Assessment by Combination Products, H2 2014 121
Number of Products by Stage and Target, H2 2014 123
Number of Products by Stage and Mechanism of Action, H2 2014 129
Number of Products by Stage and Route of Administration, H2 2014 135
Number of Products by Stage and Molecule Type, H2 2014 137
Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 326
Non-Hodgkin Lymphoma - Dormant Projects, H2 2014 431
Non-Hodgkin Lymphoma - Discontinued Products, H2 2014 434

List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2014 21
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2014 22
Number of Products under Development by Companies, H2 2014 23
Number of Products under Investigation by Universities/Institutes, H2 2014 30
Comparative Analysis by Late Stage Development, H2 2014 32
Comparative Analysis by Clinical Stage Development, H2 2014 33
Comparative Analysis by Early Stage Products, H2 2014 34
Assessment by Monotherapy Products, H2 2014 120
Number of Products by Top 10 Targets, H2 2014 122
Number of Products by Stage and Top 10 Targets, H2 2014 122
Number of Products by Top 10 Mechanism of Actions, H2 2014 128
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 128
Number of Products by Top 10 Routes of Administration, H2 2014 134
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 134
Number of Products by Top 10 Molecule Types, H2 2014 136
Number of Products by Stage and Top 10 Molecule Types, H2 2014 136

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top